Cargando…
543. Sex Differences in Clinical Presentation and Outcomes of Adults Hospitalized with COVID-19 Pneumonia After Administration of Infliximab, Abatacept or Cenicriviroc: Subgroup Analysis from the ACTIV-1 Master Protocol
BACKGROUND: A growing body of evidence suggests potential sex differences in the clinical outcomes of COVID-19. In this study we evaluated whether sex and baseline clinical variables were associated with treatment effect after receipt of immunomodulators vs placebo in a study population derived from...
Autores principales: | Rauseo, Adriana, Der, Tatyana, Alicic, Radica, Balani, Bindu, Morse, Caryn, Zakroysky, Pearl, Shaw, Linda, Atkinson, Jane, Powderly, William G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677771/ http://dx.doi.org/10.1093/ofid/ofad500.612 |
Ejemplares similares
-
Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
por: Files, Daniel Clark, et al.
Publicado: (2022) -
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011) -
Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018) -
Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
por: Diep, Laetitia, et al.
Publicado: (2022) -
Glycemic Variability and KIM-1–Induced Inflammation in the Diabetic Kidney
por: Tuttle, Katherine R., et al.
Publicado: (2021)